Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID‐19: coincidence or underestimated risk factor?

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

(2020) Daniel E. Freedberg et al.   GASTROENTEROLOGY

Adverse Events of Proton Pump Inhibitors: Potential Mechanisms

(2018) Andrea Corsonello et al.   CURRENT DRUG METABOLISM

Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A Systematic Review and Meta-Analysis

(2015) Allison A. Lambert et al.   PLoS One

Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis

(2010) C.-S. Eom et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors

(2008) M. R. Namazi et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS